XORTX Therapeutics Reports Q3 2025 Financial Results
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
XORTX Therapeutics Inc ( (TSE:XRTX) ) has provided an update.
XORTX Therapeutics Inc. released its condensed interim consolidated financial statements for the three and nine months ended September 30, 2025. The report highlights a decrease in total assets from $4,094,527 at the end of 2024 to $2,811,078 as of September 30, 2025, alongside an increase in liabilities. The financial results reflect ongoing research and development expenditures, as well as consulting and investor relations costs, which have impacted the company’s financial position. These developments may influence the company’s future operations and its ability to fund ongoing projects.
The most recent analyst rating on (TSE:XRTX) stock is a Buy with a C$14.00 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.
Spark’s Take on TSE:XRTX Stock
According to Spark, TipRanks’ AI Analyst, TSE:XRTX is a Underperform.
XORTX Therapeutics Inc faces significant challenges with no revenue and consistent losses, leading to a low financial performance score. Technical analysis indicates a neutral to bearish outlook, which, along with poor valuation metrics, weighs down the overall stock score. However, potential advancements in FDA discussions for gout treatment provide a glimmer of hope for future revenue generation, but current financial and compliance risks remain substantial.
To see Spark’s full report on TSE:XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. operates in the pharmaceutical industry, focusing on the development of therapies for kidney disease, diabetes, and cardiovascular disease. The company is based in Calgary, Alberta, and is engaged in research and development activities to advance its product pipeline.
Average Trading Volume: 12,413
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$4.51M
See more insights into XRTX stock on TipRanks’ Stock Analysis page.
